|
Sex
|
|
|
0.102 (0.01-1.08) |
0.058 |
| Male,No.(%) |
51 (94.4) |
122 (89.7) |
|
|
| Female, No. (%) |
3 (5.6) |
14 (10.3) |
|
|
|
Age, y, Mean ± SD
|
38.87 ± 10.02 |
39.61 ± 11.2 |
1.005 (0.965-1.046) |
0.818 |
|
Weight, kg, Mean ± SD
|
75.46 ± 13.83 |
74.87 ± 14.91 |
1.009 (0.982-1.036) |
0.53 |
|
Educational status
|
|
|
0.491 (0.162-1.486) |
0.208 |
| Illiterate, No. (%) |
6 (11.1) |
12 (8.8) |
|
|
| School grade, No. (%) |
47 (87) |
117 (86) |
|
|
| Academic grade, No. (%) |
1 (1.9) |
7 (5.1) |
|
|
|
Occupation
|
|
|
0.691 (0.234-2.035) |
0.502 |
| Employed, No. (%) |
41 (75.9) |
101 (74.3) |
|
|
| Unemployed, No. (%) |
13 (24.1) |
35 (25.7) |
|
|
|
Marital status
|
|
|
1.311 (0.526-3.272) |
0.561 |
| Single, No. (%) |
20 (37) |
69 (50.7) |
|
|
| Married, No. (%) |
34 (63) |
67 (49.3) |
|
|
|
Living condition
|
|
|
1.223 (0.399-3.747) |
0.725 |
| Alone, No. (%) |
10 (18.5) |
33 (24.3) |
|
|
| With family, No. (%) |
44 (81.5) |
103 (75.7) |
|
|
|
Mean monthly income, $
|
|
|
1.153 (0.548-2.423) |
0.708 |
| < 25, No. (%) |
5 (9.3) |
14 (10.3) |
|
|
| 25-125, No. (%) |
38 (70.4) |
89 (65.4) |
|
|
| > 125, No. (%) |
11 (20.4) |
33 (24.3) |
|
|
|
History of prison, No. (%)
|
35 (64.8) |
78 (57.4) |
2.069 (0.806-5.313) |
0.131 |
|
Alcohol consumption
|
|
|
0.657 (0.262-1.646) |
0.37 |
| None, No. (%) |
20 (37) |
47 (34.6) |
|
|
| Current or previous, No. (%) |
34 (63) |
89 (65.4) |
|
|
|
Smoking
|
|
|
0.085 (0.006-1.134) |
0.062 |
| None, No. (%) |
7 (13) |
21 (15.4) |
|
|
| Current or previous, No. (%) |
47 (87) |
115 (84.6) |
|
|
|
HCV genotype
|
|
|
2.031 (0.957-4.307) |
0.065 |
| 1, No. (%) |
17 (31.5) |
65 (47.8) |
|
|
| Non-1, No. (%) |
37 (68.5) |
67 (49.3) |
|
|
| Unknown, No. (%) |
0 |
4 (2.9) |
|
|
|
Route of HCV transmission
|
|
|
0.287 (0.078-1.059) |
0.061 |
| Injection of illicit drugs, No (%) |
46 (85.2) |
99 (72.8) |
|
|
| Non-injection of illicit drugs, No (%) |
4 (7.4) |
22 (16.2) |
|
|
| Unknown (%) |
4 (7.4) |
15 (11) |
|
|
|
Anti-HCV treatment regimen
|
|
|
0.562 (0.216-1.46) |
0.237 |
| Conventional interferon alpha plus Ribavirin, No.
(%) |
13 (24.1) |
25 (18.4) |
|
|
| Pegylated interferon alpha plus Ribavirin, No. (%) |
41 (75.9) |
111 (81.6) |
|
|
|
Previous anti-HCV treatment course (Mean ± SD)
|
4 (7.4) |
25 (18.4) |
0.399 (0.117-1.359) |
0.142 |
|
Concomitant diseases (Mean ± SD)
|
0.96 ± 1.027 |
1.26 ± 1.186 |
0.756 (0.512-1.118) |
0.162 |
|
Co-administered medications (Mean ± SD)
|
4.22 ± 3.142 |
4.63 ± 2.862 |
0.887 (0.741-1.062) |
0.191 |
|
Adverse drug reactions (Mean ± SD)
|
15.41 ± 9.663 |
15.43 ± 10.228 |
1.038(0.99-1.088) |
0.12 |
|
History of psychiatric disease, No. (%)
|
6 (11.1) |
23 (16.9) |
0.735(0.216-2.495) |
0.621 |
|
Family awareness about patient disease or treatment, No. (%)
|
48 (88.9) |
111 (81.6) |
1.089(0.325-3.647) |
0.891 |
|
Assistance of others in taking anti-HCV medications, No. (%)
|
21 (38.9) |
37 (27.2) |
2.69(0.636-11.366) |
0.178 |
|
Using auxiliary methods to remember anti-HCV medications, No. (%)
|
22 (40.7) |
40 (29.4) |
1.012(0.23-4.349) |
0.76 |
